Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 12, 2001
- Drug Cost Ratio Down to Record Low of 22.8%
November 12, 2001
- WORLD NEWS IN BRIEF
November 12, 2001
- BULLETIN
November 12, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 12, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
November 12, 2001
- EFPIA Stresses That Reforms Are Needed to Promote Innovation
November 12, 2001
- Sankyo Planning Late PII Study on Pitavastatin in US
November 12, 2001
- REGULATORY NEWS IN BRIEF
November 5, 2001
- JABEX Calls For Policy to Make Japan Bioindustry-based Nation
November 5, 2001
- JPA Opposes Healthcare Cost Ceiling System
November 5, 2001
- Healthcare Services Incompatible with Market Economy: JMA Seminar
November 5, 2001
- Prozac, Evista to Boost Eli Lilly Japan to Enter Top 10 by 2010: President Mascarenhas
November 5, 2001
- JMA Presents Proposals for Financial Reconstruction of Health Insurance Programs
November 5, 2001
- J&J to Buy Out Kyowa Hakko's Interest in Janssen Kyowa
November 5, 2001
- PMS Is Important for Products Approved via Bridging Studies: PMDEC
November 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 5, 2001
- Drug Classification Table for Selection of Comparator Drugs Approved by Chuikyo
November 5, 2001
- Yutaka Pharmacy Ties Up with Drug Lion, Reaching Sales of \50 Bil.
November 5, 2001
- Reduction in Price Adjustment Zone Below 2% Is Inappropriate: Korosho Director
November 5, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…